Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Neumentum Inc.

www.neumentum.com

Latest From Neumentum Inc.

Deal Watch: GSK Furthers Cancer Gene Therapy Plans Via Lyell Collaboration

GSK hopes the San Francisco biotech’s technology can help its cell therapy pipeline address solid tumors. Avacta partners with ADC on antibody-drug conjugates.

Deals Business Strategies

Venture Funding Deals: Orchard Therapeutics Spreads Its Roots

Rare disease gene therapy play Orchard added new investors in an oversubscribed Series B raising $110m and therapeutic antibody developer Allakos raised $100m in its Series B round, while Obsidian raises $49.5m for next-generation cancer cell therapies in Series A.

StartUps and SMEs Financing
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • Neumentum Inc.
  • Senior Management
  • R. Scott Shively, CEO
    Ilona Steigerwald, MD, CMO
    Robert B Raffa, PhD, CSO
    Christine Mikail, CBO
    Sarah Howlett Faust, Chief Commercial Officer
  • Contact Info
  • Neumentum Inc.
    Phone: (833) 638-7246
    252 Colorado Ave.
    Palo Alto, CA 94301
    USA
UsernamePublicRestriction

Register